The proxy fight outcome is uncertain — management holds 18.1% insider ownership and has a $25M buyback program, but Radoff/Torok have made multiple acquisition proposals. Monitor ISS/Glass Lewis recommendations and institutional shareholder voting patterns ahead of July 28 meeting. A dissident win could accelerate a sale process; a management win maintains status quo with potential for further buybacks.
Price Chart
Executive Summary
Seer's board filed definitive additional proxy soliciting materials urging stockholders to vote FOR management's seven director nominees at the July 28, 2026 annual meeting, opposing activist Bradley Radoff and Michael Torok's proxy contest to elect three dissident nominees. The filing details the board's rejection of Radoff/Torok's latest $141M acquisition proposal as significantly undervaluing the company relative to its ~$220M cash position, and argues the dissident nominees lack relevant life sciences expertise.
Key Financial Metrics
Key Facts
- Annual meeting scheduled for July 28, 2026; seven management director nominees vs. three dissident nominees from Radoff/Torok (7.8% owners)
- Board unanimously rejected Radoff/Torok's May 14, 2026 acquisition proposal of ~$141M, citing ~$220M cash/cash equivalents/investments as of March 31, 2026 and no debt
- Board and management collectively own 18.1% of outstanding shares
- Since 2024, Seer repurchased ~13.2M shares at VWAP $1.86 (~$24.5M), reducing net shares by ~15%; new $25M buyback program announced February 2026
- Q1 2026 operating expenses reduced to $18.2M from $22.8M in Q1 2025; installed base grew 67% YoY, consumable kit volumes up 69%
- Insider ownership 18.1%; no equity awards granted to management in 2025
- Radoff/Torok nominees: Howard Berman (biopharma, no proteomics), Joshua Horowitz (investor, no life sciences), Luis Rinaldini (telecom banker, no life sciences)
Financial Impact
Dissident offer of ~$141M vs. ~$220M cash on balance sheet; board claims offer significantly undervalues company. Company has no debt.
Risk Factors
- Dissident nominees could win board seats, potentially forcing a sale at a discount to cash value
- Proxy fight diverts management attention from commercial execution
- Stock trades below cash value (~$220M cash vs $103M market cap), signaling market skepticism about turnaround
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-255785 |
| Document: 0001193125-26-255785-index-headers.html | 0001193125-26-255785 |
| Document: 0001193125-26-255785-index.html | 0001193125-26-255785 |
| Document: 0001193125-26-255785.txt | 0001193125-26-255785 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Press Release | $1.97 | awaiting T+20 | — | $1.98 (+0.51%) |
Oct 15, 2026 12d ago | ITC Section 337 | $2.03 | awaiting T+20 | — | $1.98 (−2.46%) |
Oct 8, 2026 18d ago | 3 | $2.19 | awaiting T+20 | — | $1.98 (−9.59%) |
Sep 21, 2026 5w ago | Press Release | $1.86 $2.02 | ▲ +8.60% | ▲ +9.51% | $1.98 (+6.45%) |
Jul 31, 2026 12w ago | 8-K | $2.22 $1.98 | ▼ −10.81% | ▼ −13.80% | $1.98 (−10.81%) |
Jul 28, 2026 12w ago | Press Release | $2.08 $2.02 | ▲ +2.88% | ▲ +7.90% | $1.98 (+4.81%) |
Jul 28, 2026 12w ago | DFAN14A | $2.14 $2.04 | ▼ −4.67% | ▼ −8.05% | $1.98 (−7.48%) |
Jul 20, 2026 14w ago | DEFA14A | $2.04 $2.03 | ▼ −0.49% | ▼ −4.61% | $1.98 (−2.94%) |
Jul 20, 2026 14w ago | Press Release | $2.04 $2.03 | ▼ −0.49% | ▼ −4.61% | $1.98 (−2.94%) |
Jul 8, 2026 15w ago | DEFA14A | $2.18 $2.19 | ▲ +0.46% | ▼ −2.81% | $1.98 (−9.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers